In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.
Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...
Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital orga ...
A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Understand the nurse’s role in managing hypertension and helping patients manage their blood pressure to reduce the risk of ...
More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback